# Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

> **NCT06943664** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 27 (estimated)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Refractory Lung Non-Small Cell Carcinoma
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Cemiplimab
- **BIOLOGICAL:** Cetuximab Sarotalocan Sodium
- **PROCEDURE:** Computed Tomography
- **OTHER:** Electronic Health Record Review
- **PROCEDURE:** Endobronchial Ultrasound Bronchoscopy
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Photoimmunotherapy
- **PROCEDURE:** Photoimmunotherapy
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Robotic Bronchoscopy
- **PROCEDURE:** Video-Assisted Thoracic Surgery

## Key facts

- **NCT ID:** NCT06943664
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943664, "Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06943664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*